RANI Key Statistics, Chart & Performance
The current stock price of RANI is 1.635 USD. In the past month the price decreased by -29.96%. In the past year, price decreased by -17.62%.
RANI Latest News, Press Relases and Analysis
RANI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.4 | 943.76B | ||
| JNJ | JOHNSON & JOHNSON | 19.42 | 485.62B | ||
| MRK | MERCK & CO. INC. | 11.11 | 243.01B | ||
| PFE | PFIZER INC | 8.07 | 146.78B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.93 | 105.94B | ||
| ZTS | ZOETIS INC | 18.57 | 51.87B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.52 | 22.58B | ||
| VTRS | VIATRIS INC | 4.76 | 12.78B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.71 | 10.83B | ||
| CORT | CORCEPT THERAPEUTICS INC | 97.47 | 9.02B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.57B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.28B |
Related stock screener links
About RANI
Company Profile
Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company is headquartered in San Jose, California and currently employs 105 full-time employees. The company went IPO on 2021-07-30. The firm has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The company has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. The company is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
Company Info
RANI THERAPEUTICS HOLDINGS-A
2051 Ringwood Avenue
San Jose CALIFORNIA US
CEO: Talat Imran
Employees: 105
Phone: 14084573700
RANI THERAPEUTICS HOLDINGS-A / RANI FAQ
Can you describe the business of RANI THERAPEUTICS HOLDINGS-A?
Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company is headquartered in San Jose, California and currently employs 105 full-time employees. The company went IPO on 2021-07-30. The firm has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The company has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. The company is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
What is the current price of RANI stock?
The current stock price of RANI is 1.635 USD. The price increased by 2.83% in the last trading session.
Does RANI stock pay dividends?
RANI does not pay a dividend.
What is the ChartMill technical and fundamental rating of RANI stock?
RANI has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the employee count for RANI stock?
RANI THERAPEUTICS HOLDINGS-A (RANI) currently has 105 employees.
What is the ownership structure of RANI THERAPEUTICS HOLDINGS-A (RANI)?
You can find the ownership structure of RANI THERAPEUTICS HOLDINGS-A (RANI) on the Ownership tab.
RANI Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to RANI. When comparing the yearly performance of all stocks, RANI is one of the better performing stocks in the market, outperforming 96.93% of all stocks.
RANI Financial Highlights
Over the last trailing twelve months RANI reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS increased by 25.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -279.27% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
RANI Forecast & Estimates
9 analysts have analysed RANI and the average price target is 9.44 USD. This implies a price increase of 477.06% is expected in the next year compared to the current price of 1.635.